Cargando…
Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer
PD-L1 expression is elevated in various human cancers, including colorectal cancer. High levels of PD-L1 expressed on tumor epithelial cells are one of the potential mechanisms by which tumor cells become resistant to immune attack. However, PD-L1 regulation in tumor cells is not fully understood. H...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526383/ https://www.ncbi.nlm.nih.gov/pubmed/34385594 http://dx.doi.org/10.1038/s41388-021-01972-6 |
Sumario: | PD-L1 expression is elevated in various human cancers, including colorectal cancer. High levels of PD-L1 expressed on tumor epithelial cells are one of the potential mechanisms by which tumor cells become resistant to immune attack. However, PD-L1 regulation in tumor cells is not fully understood. Here we demonstrate that mutations in the Adenomatous Polyposis Coli (APC) gene lead to colonic epithelial cell resistance to CD8(+) T cell cytotoxicity by induction of PD-L1 expression. Mechanistically this occurs as a result of the β-catenin/TCF4 complex binding to the PD-L1 promoter, leading to increased transcription. Our findings not only reveal a novel mechanism by which APC mutations induce tumor immune evasion via an immune checkpoint pathway, but also pave the way for developing β-catenin or TCF4 inhibitors as possible new options for immune checkpoint inhibition. |
---|